REBEC

Public trial

Dietary intervention to reduce ultra-processed foods in women with Temporomandibular Disorder

Date of registration: 07/21/2026 ^(mm/dd/yyyy)
Last approval date : 07/21/2026 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Effects of different doses of caffeine on energy expenditure, heart rate, blood pressure, and blood lipids in healthy adults

Date of registration: 07/21/2026 ^(mm/dd/yyyy)
Last approval date : 07/21/2026 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Evaluation of an educational program for Primary Health Care users with Type 2 Diabetes Mellitus

Date of registration: 03/18/2024 ^(mm/dd/yyyy)
Last approval date : 07/21/2026 ^(mm/dd/yyyy)
Last revision: 3

Study type:

Interventional

Effects of Physiotherapy after Knee Replacement

Date of registration: 07/21/2026 ^(mm/dd/yyyy)
Last approval date : 07/21/2026 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Analysis of the efficacy and tolerability of the treatment of Motor and Vocal Tic Disorder using Magnetic Stimulation on the skull

Date of registration: 07/21/2026 ^(mm/dd/yyyy)
Last approval date : 07/21/2026 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Effect of pH of Whitening Gels on color change and sensitivity in patients with aesthetic restorations

Date of registration: 07/21/2026 ^(mm/dd/yyyy)
Last approval date : 07/21/2026 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

How a Medication that increases Glucose Elimination through the Kidneys may affect inflammation and blood vessel health in people with Obesity

Date of registration: 07/21/2026 ^(mm/dd/yyyy)
Last approval date : 07/21/2026 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Integrated training program for adults - PrATI

Date of registration: 07/21/2026 ^(mm/dd/yyyy)
Last approval date : 07/21/2026 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

BRACE: Brazilian endometrial Cancer characterization

Date of registration: 07/17/2026 ^(mm/dd/yyyy)
Last approval date : 07/21/2026 ^(mm/dd/yyyy)
Last revision: 2

Study type:

Observational

Effects of Balance Rehabilitation in Older Adults with Vestibular Disorders and Mild Cognitive Impairment

Date of registration: 07/21/2026 ^(mm/dd/yyyy)
Last approval date : 07/21/2026 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Effect of using beta-glucans on immunity and treatment continuity for women with breast cancer BioVit Trial

Date of registration: 07/20/2026 ^(mm/dd/yyyy)
Last approval date : 07/20/2026 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Effect of a Protein-rich Supplement and its natural components on the health and nutritional status of people with Head and Neck Cancer

Date of registration: 07/20/2026 ^(mm/dd/yyyy)
Last approval date : 07/20/2026 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Virtual reality enhances the effects of transcranial electrical stimulation on pain and quality of life in patients with Fibromyalgia: a randomized clinical trial

Date of registration: 07/20/2026 ^(mm/dd/yyyy)
Last approval date : 07/20/2026 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Complete Upper and Lower Limb Rehabilitation System for Post-Stroke Patients Using Brain-Computer Interface, Rehabilitation Robots, and Brain Stimulation Techniques

Date of registration: 07/20/2026 ^(mm/dd/yyyy)
Last approval date : 07/20/2026 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Efficacy of multimodal training with several types of exercises to increase walking ability and improve heart function in people affected by stroke

Date of registration: 03/13/2024 ^(mm/dd/yyyy)
Last approval date : 07/20/2026 ^(mm/dd/yyyy)
Last revision: 3

Study type:

Interventional

Hypothesis Trial: Hypofractionated versus Conventional Radiotherapy with Concurrent Cisplatin in Locally Advanced Cervical Cancer

Date of registration: 07/20/2026 ^(mm/dd/yyyy)
Last approval date : 07/20/2026 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Low-level laser therapy to aid wound healing

Date of registration: 07/20/2026 ^(mm/dd/yyyy)
Last approval date : 07/20/2026 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Effects of Breakfast and Physical Exercise on attention and reasoning in university students: a randomized clinical trial

Date of registration: 07/20/2026 ^(mm/dd/yyyy)
Last approval date : 07/20/2026 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Comparison of two articaine-based local anesthetics available in Brazil for wisdom tooth removal

Date of registration: 07/20/2026 ^(mm/dd/yyyy)
Last approval date : 07/20/2026 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Influence of hydrotherapy on the function of pelvic floor muscles in women with gestational diabetes.

Date of registration: 07/20/2026 ^(mm/dd/yyyy)
Last approval date : 07/20/2026 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Username/Password

News

08/27/2026

First participant dosed in the PRECISE-HD trial of pridopidine

08/27/2026 | Dr Rachel Harding | HD Buzz

https://en.hdbuzz.net/first-participant-dosed-in-the-precise-hd-trial-of-pridopidine/

First participant dosed in the PRECISE-HD trial of pridopidine
The first participant has now been dosed in the Phase 3 PRECISE-HD trial of pridopidine for HD. The study will test whether the drug can slow disease progression in people most likely to benefit

new Huntington’s disease (HD) clinical trial has officially begun, marking another important step in the search for treatments that could slow the progression of the disease. Prilenia Therapeutics and Ferrer have announced via a Linkedin post that the first participant has been dosed in the PRECISE-HD Phase 3 clinical trial, which is testing the investigational drug pridopidine.

Another chance for pridopidine
Long-time HDBuzz readers may recognise pridopidine. Pridopidine has had one of the longest and most winding development journeys of any experimental HD therapy. Originally developed as a treatment for movement symptoms, early clinical trials failed to meet their primary goals despite nuanced hints of benefit on some tests.

In 2023, the large Phase 3 PROOF-HD study did not meet its primary goal of slowing disease progression across all participants. However, a planned analysis of the data suggested that people who were not taking antidopaminergic medications (ADMs) appeared to have greater benefit from pridopidine than those who were taking these medications. ADMs are drugs commonly prescribed to treat chorea or psychiatric symptoms.

Those findings prompted discussions with regulators and the HD community about how best to determine whether this apparent benefit was real. What emerged is PRECISE-HD: a new confirmatory trial specifically designed to test…

08/27/2026

African Bundibugyo ebolavirus vaccine candidate to be advanced to clinical trials

08//26/2026 | CEPI

https://cepi.net/african-bundibugyo-ebolavirus-vaccine-candidate-be-advanced-clinical-trials

Leading African biopharmaceutical company Minapharm Group, headquartered in Egypt with subsidiaries in Berlin, will receive up to US$16.5 million from the Coalition for Epidemic Preparedness Innovations (CEPI) to advance the development of a Bundibugyo ebolavirus vaccine candidate, strengthening efforts to develop vaccines to combat the fastest-growing and second-largest Ebola outbreak on record affecting the Democratic Republic of the Congo (DRC).

Minapharm’s Bundibugyo vaccine is designed by ProBioGen, a Berlin-based specialist within Minapharm Group, based on their proprietary modified vaccinia Ankara (MVA) vaccine platform, MVA-CR19. A similar technology underpins a licensed vaccine against smallpox and mpox, and has elicited long-term immunity in a vaccine targeting the related Zaire ebolavirus.

CEPI’s funding will advance the Bundibugyo vaccine candidate through preclinical development and into an early-stage clinical trial to assess the immunogenicity and safety of the vaccine candidate. The study in humans, known as a Phase 1 trial, is expected to take place in Africa.

Minapharm’s investigational vaccine becomes the fifth Bundibugyo-specific virus vaccine candidate supported by CEPI in response to the escalating epidemic. It joins a portfolio of promising CEPI-backed candidates* built on different vaccine technologies to maximise the likelihood of developing a safe and effective shot that could help bring this devastating crisis under control.

It is the only Bundibugyo vaccine candidate CEPI is funding that is designed to induce both B- and T-cell responses for comprehensive and long-lasting immunity.

“CEPI’s funding to Minapharm harnesses…

08/27/2026

Alliance releases new film highlighting the critical role of clinical trials

08/27/2026 | News Medical

https://www.news-medical.net/news/20260827/Alliance-releases-new-film-highlighting-the-critical-role-of-clinical-trials.aspx

The Alliance for Clinical Trials in Oncology has released a film highlighting the critical role of participant involvement in advancing cancer research and improving care.

Presented by the Union for International Cancer Control (UICC) and produced for us by BBC StoryWorks Commercial Productions as part of the global Rewriting Cancer series, the feature tells the story of JaTaun Williams, a 68-year-old Chicago-based special education teacher diagnosed with lung cancer after seeking care for COVID-19 like symptoms. Upon her diagnosis, Williams chose to enroll in a clinical trial as part of her treatment. She shares her experience to help others understand the importance of clinical trials and how individual participation contributes to progress in cancer research.

Rather than focusing on a specific trial, the film emphasizes the human element of research; exploring the decision-making process behind trial participation and highlight how volunteers gain access to innovative treatments while contributing to future advancement in cancer care.

Clinical trials are an essential part of making progress against cancer, often leading to FDA approvals, influencing national guidelines and creating new standards of care. This film offers us an opportunity to showcase patients like Mrs. Williams and the tens of thousands of individuals like her who have participated in Alliance trials over the decades, donating their time and entrusting us with their care." Evanthia Galanis, MD, DSc, Group Chair, Alliance for Clinical Trials in Oncology

Funding support was provided from Natera, Inc., in partnership with the Alliance…

08/26/2026

Asia’s clinical research revolution: Why the world’s innovation centre is shifting east

08/25/2026 | Clinical Trials Arena

https://www.clinicaltrialsarena.com/sponsored/asias-clinical-research-revolution-why-the-worlds-innovation-centre-is-shifting-east/

Backed by sustained government investment, regulatory reform and growing biotech ecosystems, China, Japan and South Korea are reshaping global drug development and offering valuable lessons for other regions looking to remain competitive.

he global map of clinical research is changing rapidly. Once viewed primarily as an attractive destination for cost-efficient clinical trials, the Asia-Pacific (APAC) region is now driving innovation across the pharmaceutical industry, with governments, regulators and private investors working together to accelerate drug development.

Clinical trial activity illustrates the scale of this transformation. APAC contributes an estimated 43% of the world’s innovative treatment pipeline, with metabolic and cardiovascular disease therapeutic areas in particular experiencing rapid expansion. The APAC market is marked by an estimated cardiovascular drug value reaching USD 12.60 billion, a metabolic therapeutics sector growing at over 8% CAGR.

Clinical understanding in 2026 emphasises that Asian populations develop metabolic and cardiovascular risk factors at a lower body mass index (BMI) than Western populations, accelerating local screening and early intervention protocols. As such, APAC continues to serve as a major hub for early-phase and multi-regional clinical trials (MRCTs), bolstered by modernised regulatory pathways and expansive local patient demographics.

But demand for clinical research across a broad range of therapies is rising in APAC, with key countries strengthening the foundations needed for globally competitive trials, including regulatory…

08/26/2026

Trial complexity grows amid shift in R&D focus, legislation and tech advances

08/26/2026 | Gareth Macdonald | BioXconomy

https://www.bioxconomy.com/clinical-and-research/trial-complexity-grows-amid-shift-in-rd-focus-legislation-and-tech-advances

Collecting superfluous clinical trial information unrelated to key endpoints creates unnecessary burdens on patients, sites and sponsors, say experts.

Growing complexity is often cited as a challenge for the trials sector, partly driven by biopharma’s shift toward hard-to-treat diseases. However, another factor making trials harder is the practice of gathering non-core data, researchers say.

Estimates vary, but most observers agree it costs between $2 billion and $2.6 billion and takes 10 to 15 years to develop a biopharmaceutical, a considerable proportion of which is spent on clinical trials.

Trials are expensive, in part, because they are technically challenging, according to recent analysis by investment bank Bourne Partners, which suggests that the growing focus on difficult diseases is a root cause.

Head of research Donald Hooker told BioXconomy, “Sponsors continue to struggle with increasing clinical trial complexity and rising drug development costs.

“A larger driver of the increasing complexity is therapeutic mix. For instance, oncology, central nervous system disorders, and infectious diseases are increasingly dominating the clinical trial pipeline. Each of these therapeutic categories brings with it significant complexity and data management challenges,” he said.

In the US, recent legislative measures – such as the One Big Beautiful Bill Act and the Inflation Reduction Act – are also impacting the types of diseases developers target, according to Hooker.

“Recent legislation incentivizes investments in…